MA32225B1 - Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c - Google Patents

Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c

Info

Publication number
MA32225B1
MA32225B1 MA33242A MA33242A MA32225B1 MA 32225 B1 MA32225 B1 MA 32225B1 MA 33242 A MA33242 A MA 33242A MA 33242 A MA33242 A MA 33242A MA 32225 B1 MA32225 B1 MA 32225B1
Authority
MA
Morocco
Prior art keywords
hepatitis
methods
virus replication
macrocyclic inhibitors
compound
Prior art date
Application number
MA33242A
Other languages
Arabic (ar)
English (en)
Inventor
Leonid Beigelman
Brad Buckman
Antitsa Dimitrova Stoycheva
Steven B Porter
Williamson Ziegler Bradford
Vladimir Serebryany
Scott Seiwert
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of MA32225B1 publication Critical patent/MA32225B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Les modes de réalisation de la présente invention concernent des composés de formules générales i, ii, ei, iv, v, vi, vii, et x, ainsi que des compositions, y compris des compositions pharmaceutiques, comprenant un composé de l'invention. Les modes de réalisation concernent en outre des procédés thérapeutiques, y compris des procédés permettant de traiter l'infection par le virus de l'hépatite c et des procédés permettant de traiter la fibrose hépatique, les procédés impliquant généralement l'administration à un individu en ayant besoin d'une quantité efficace d'un composé ou d'une composition de l'invention.
MA33242A 2008-04-15 2010-10-11 Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c MA32225B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4522008P 2008-04-15 2008-04-15
US10573608P 2008-10-15 2008-10-15
US10575108P 2008-10-15 2008-10-15
US14372809P 2009-01-09 2009-01-09
US15069309P 2009-02-06 2009-02-06
PCT/US2009/040565 WO2009142842A2 (fr) 2008-04-15 2009-04-14 Nouveaux inhibiteurs macrocycliques de la réplication du virus de l’hépatite c

Publications (1)

Publication Number Publication Date
MA32225B1 true MA32225B1 (fr) 2011-04-01

Family

ID=41215217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33242A MA32225B1 (fr) 2008-04-15 2010-10-11 Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c

Country Status (22)

Country Link
US (2) US8048862B2 (fr)
EP (1) EP2282762A2 (fr)
JP (1) JP2011519364A (fr)
KR (1) KR20110005869A (fr)
CN (1) CN102046622A (fr)
AP (1) AP2010005416A0 (fr)
AR (1) AR072779A1 (fr)
AU (1) AU2009249443A1 (fr)
BR (1) BRPI0911260A2 (fr)
CA (1) CA2720729A1 (fr)
CO (1) CO6321290A2 (fr)
CU (1) CU20100203A7 (fr)
EA (1) EA201071034A1 (fr)
EC (1) ECSP10010612A (fr)
IL (1) IL208529A0 (fr)
MA (1) MA32225B1 (fr)
MX (1) MX2010011306A (fr)
NI (1) NI201000174A (fr)
SG (1) SG175692A1 (fr)
TW (1) TW200948376A (fr)
WO (1) WO2009142842A2 (fr)
ZA (1) ZA201007256B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP2305696A3 (fr) * 2005-07-25 2011-10-12 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
KR20080056295A (ko) * 2005-10-11 2008-06-20 인터뮨, 인크. Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
AP2009005057A0 (en) 2007-05-10 2009-12-31 Array Biopharma Inc Novel peptide inhibitors of hepatitis c virus replication
AU2009249443A1 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
EP2393493A4 (fr) * 2009-01-30 2013-07-17 Glaxosmithkline Llc Composés
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN102712644A (zh) * 2009-09-28 2012-10-03 豪夫迈·罗氏有限公司 丙肝病毒复制的新型大环抑制剂
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
WO2011041551A1 (fr) * 2009-10-01 2011-04-07 Intermune, Inc. Peptides antiviraux thérapeutiques
US8653025B2 (en) * 2010-01-27 2014-02-18 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
CA2792601C (fr) * 2010-03-10 2015-09-29 Abbott Laboratories Compositions solides d'inhibiteurs de vhc amorphes
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
US20120101032A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN103328466B (zh) 2010-11-01 2016-08-03 Rfs制药公司 Hcv ns3蛋白酶抑制剂
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012092411A2 (fr) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques de phénanthridine de sérine protéase d'hépatite c
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (fr) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 Composé hétérocyclique macrocyclique pour l'inhibition du virus de l'hépatite c, sa préparation et ses applications
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2802595B1 (fr) 2012-01-11 2016-01-06 AbbVie Inc. Procédés de préparation d'inhibiteurs de protéase du vhc
CN104039774A (zh) 2012-01-12 2014-09-10 Rfs制药公司 Hcv ns3蛋白酶抑制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP2015533124A (ja) 2012-10-08 2015-11-19 アッヴィ・インコーポレイテッド Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070974A1 (fr) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
CN104311544A (zh) * 2014-09-22 2015-01-28 湖南华腾制药有限公司 一种苯并恶唑衍生物的制备方法
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
CN104327061A (zh) * 2014-10-19 2015-02-04 湖南华腾制药有限公司 一种溴苯并[d]恶唑衍生物的制备方法
WO2016127859A1 (fr) * 2015-02-13 2016-08-18 Sunshine Lake Pharma Co., Ltd. Composés utilisés en tant qu'inhibiteurs du virus de l'hépatite c et leurs utilisations en médecine
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
CN109616152B (zh) * 2018-12-06 2020-01-03 中国人民解放军军事科学院军事医学研究院 癌症特异的共调网络建立方法及装置

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
ATE108794T1 (de) 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5232928A (en) 1989-07-25 1993-08-03 Boehringer Ingelheim Pharmaceuticals, Inc. Tetrahydroisoquinoline amides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6693072B2 (en) * 1994-06-02 2004-02-17 Aventis Pharmaceuticals Inc. Elastase inhibitors
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
DE60137207D1 (de) * 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
SK14952002A3 (sk) * 2000-04-19 2003-03-04 Schering Corporation Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
PL206255B1 (pl) * 2000-07-21 2010-07-30 Dendreon Corporationdendreon Corporation Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
JP3889708B2 (ja) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎トリペプチド阻害剤
EP1408986B1 (fr) 2001-05-08 2008-09-24 Yale University Composes proteomimetiques et procedes correspondants
CN100402549C (zh) * 2001-07-11 2008-07-16 沃泰克斯药物股份有限公司 桥连二环的丝氨酸蛋白酶抑制剂
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (fr) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370400A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CA2369970A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
NZ561851A (en) * 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
WO2003091264A2 (fr) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Inhibiteurs non nucleosidiques de la transcriptase inverse
WO2004043339A2 (fr) * 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
EP1506000B9 (fr) * 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003299519A1 (en) * 2002-05-20 2004-05-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
DE10246957A1 (de) * 2002-10-09 2004-04-22 Bayer Ag Polycarbonat enthaltend Diphenylcarbonat und Platten enthaltend dieses Polycarbonat
PL199412B1 (pl) 2002-10-15 2008-09-30 Boehringer Ingelheim Int Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
CA2520886A1 (fr) * 2003-04-02 2004-11-04 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques contenant des inhibiteurs de protease virale de l'hepatite c
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2386161T3 (es) * 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US20040229848A1 (en) 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AU2004274468B2 (en) * 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP4525982B2 (ja) * 2003-09-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼの大環状インヒビター
KR20120010278A (ko) * 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
PL1680137T3 (pl) * 2003-10-14 2013-04-30 F Hoffmann La Roche Ltd Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV
CA2551074A1 (fr) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Mutants resistant a la protease hcv ns3-ns4a
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005053735A1 (fr) * 2003-11-20 2005-06-16 Boehringer Ingelheim International Gmbh Procede d'elimination de metaux de transition, notamment, a partir de produits de reaction de metathese
JP2007532479A (ja) * 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
AU2004298498B2 (en) 2003-12-11 2008-09-11 Schering Corporation Inhibitors of hepatitis C virus NS3/NS4a serine protease
ES2358333T3 (es) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
WO2005077969A2 (fr) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
WO2005087730A1 (fr) 2004-02-27 2005-09-22 Schering Corporation Composes de proline fusionnes a 3,4-(cyclopentyl) en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
JP4874227B2 (ja) * 2004-02-27 2012-02-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド
EP1939213B1 (fr) 2004-02-27 2010-08-25 Schering Corporation Nouveaux composés en tant qu'inhibiteurs de la sérine protéase NS3 du virus de l'hépatite C
KR20060124725A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 프로테아제의 억제제
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
AU2005224092A1 (en) 2004-03-15 2005-09-29 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis C viral infections
CN1984922A (zh) 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
US7514557B2 (en) 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US20060069316A1 (en) * 2004-07-02 2006-03-30 Discus Dental Impressions, Inc. Retracting devices
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
AP2461A (en) * 2004-07-16 2012-09-14 Gilead Sciences Inc Antiviral compounds
JP4914355B2 (ja) * 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
CN101068828A (zh) * 2004-08-27 2007-11-07 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
EP1794179A1 (fr) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Réaction de métathèse cyclisante en milieu fluide supercritique
CA2577831A1 (fr) 2004-09-17 2006-03-30 Boehringer Ingelheim International Gmbh Procede de fabrication d'inhibiteurs de protease hcv macrocycliques
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
AU2006220887B2 (en) 2005-03-04 2010-11-04 The Rockefeller University Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof
KR101514953B1 (ko) 2005-03-08 2015-04-24 베링거 인겔하임 인터내셔날 게엠베하 매크로사이클릭 화합물의 제조방법
CA2606195C (fr) * 2005-05-02 2015-03-31 Merck And Co., Inc. Inhibiteurs de la protease ns3 du vhc
EP1899368A2 (fr) 2005-05-26 2008-03-19 Schering Corporation Fusion interferon-igg
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP2305696A3 (fr) 2005-07-25 2011-10-12 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
DK1912997T3 (da) * 2005-07-29 2012-01-02 Tibotec Pharm Ltd Makrocycliske inhibitorer af hepatitis C virus
KR20080056295A (ko) * 2005-10-11 2008-06-20 인터뮨, 인크. Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
WO2007057317A1 (fr) * 2005-11-16 2007-05-24 F. Hoffmann-La Roche Ag DERIVES INNOVANTS DE LA PYRROLIDINE EN TANT QU'INHIBITEURS DU FACTEUR DE COAGULATION Xa
MX2008011868A (es) * 2006-03-16 2008-12-15 Vertex Pharma Inhibidores deuterados de la proteasa de la hepatitis c.
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US20090203008A1 (en) 2006-06-08 2009-08-13 Ludmerer Steven W Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
JP2009542698A (ja) * 2006-07-07 2009-12-03 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルスホスフィナート化合物
EP2049474B1 (fr) * 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
ES2448494T3 (es) * 2006-07-13 2014-03-14 Achillion Pharmaceuticals, Inc. Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral
CN101674844A (zh) * 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2009005219A (es) * 2006-11-17 2009-05-27 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de hepatitis c.
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2676297A1 (fr) * 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibiteurs de la ns3 protease de l'hepatite c
US20100074867A1 (en) * 2007-03-23 2010-03-25 Schering Corporation Patent Department, K-6-1; 1990 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
AU2008240834B2 (en) 2007-04-24 2012-08-23 F. Hoffmann-La Roche Ag Process for HCV protease inhibitor intermediate
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20090123423A1 (en) * 2007-04-26 2009-05-14 Yonghua Gai Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
WO2008134395A1 (fr) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques azapeptidiques des protéases à sérine du virus de l'hépatite c
US7910587B2 (en) 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20080274082A1 (en) 2007-04-26 2008-11-06 Yonghua Gai Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
US20080317712A1 (en) 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
AP2009005057A0 (en) 2007-05-10 2009-12-31 Array Biopharma Inc Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009014730A1 (fr) * 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
US20090060874A1 (en) * 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
JP2010540549A (ja) * 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
WO2009055335A2 (fr) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Inhibiteurs des protéases du vhc
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
WO2009076166A2 (fr) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyles de la sérine protéase de vhc
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
CN101903391B (zh) 2007-12-21 2013-04-03 弗·哈夫曼-拉罗切有限公司 大环化合物的制备方法
WO2009099596A2 (fr) 2008-02-04 2009-08-13 Idenix Pharamaceuticals, Inc. Inhibiteurs de sérine protéase macrocycliques
EP2237793A4 (fr) 2008-02-07 2013-07-31 Virobay Inc Inhibiteurs de la cathepsine b
SI2276725T1 (sl) 2008-04-11 2012-09-28 Hoffmann La Roche Novi rutenijevi kompleksi kot katalizatorji za metatezne reakcije
AU2009249443A1 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
WO2009134987A1 (fr) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Composés macrocycliques contenant du difluorométhyle comme inhibiteurs du virus de l’hépatite c
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
WO2009148923A1 (fr) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Inhibiteurs du virus de l’hépatite c
KR20110065440A (ko) * 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8603737B2 (en) * 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
NZ592110A (en) * 2008-11-20 2012-06-29 Achillion Pharmaceuticals Inc Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
EP2364310B1 (fr) 2008-12-10 2015-07-29 Achillion Pharmaceuticals, Inc. Analogues cycliques de peptides a-amino-4-oxobutanoyl, inhibiteurs de la réplication virale
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110114582A (ko) 2008-12-19 2011-10-19 길리애드 사이언시즈, 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제
AR074758A1 (es) 2008-12-22 2011-02-09 Gilead Sciences Inc Compuestos macrociclicos antivirales
EP2393493A4 (fr) 2009-01-30 2013-07-17 Glaxosmithkline Llc Composés
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2417134B1 (fr) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Inhibiteurs macrocycliques de la sérine protéase
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN102712644A (zh) * 2009-09-28 2012-10-03 豪夫迈·罗氏有限公司 丙肝病毒复制的新型大环抑制剂
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
WO2011041551A1 (fr) * 2009-10-01 2011-04-07 Intermune, Inc. Peptides antiviraux thérapeutiques

Also Published As

Publication number Publication date
BRPI0911260A2 (pt) 2015-09-29
EP2282762A2 (fr) 2011-02-16
CU20100203A7 (es) 2012-06-21
SG175692A1 (en) 2011-11-28
US20110059047A1 (en) 2011-03-10
CA2720729A1 (fr) 2009-11-26
AU2009249443A1 (en) 2009-11-26
WO2009142842A9 (fr) 2010-11-25
ECSP10010612A (es) 2010-12-30
MX2010011306A (es) 2010-11-09
JP2011519364A (ja) 2011-07-07
CN102046622A (zh) 2011-05-04
US8048862B2 (en) 2011-11-01
AR072779A1 (es) 2010-09-22
ZA201007256B (en) 2013-03-27
WO2009142842A2 (fr) 2009-11-26
KR20110005869A (ko) 2011-01-19
AP2010005416A0 (en) 2010-10-31
WO2009142842A3 (fr) 2010-04-01
TW200948376A (en) 2009-12-01
CO6321290A2 (es) 2011-09-20
US20090269305A1 (en) 2009-10-29
NI201000174A (es) 2011-08-24
IL208529A0 (en) 2010-12-30
EA201071034A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
MA32225B1 (fr) Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
MA33720B1 (fr) Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite c
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
WO2008005511A3 (fr) Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2009134616A3 (fr) Nouveaux inhibiteurs de réplication du virus de l’hépatite c
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
ES2571730T3 (es) Composiciones farmacéuticas que comprenden droxidopa
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
MA33658B1 (fr) N-4(-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phényl)-4-(4-méthyl-2- thiényl)-1-phtalazinamine destinée à être utilisée dans le traitement d'un cancer résistant aux agents antimitotiques
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
MA31252B1 (fr) Macrolides a base d'erythromycine
WO2007109363A3 (fr) Procédés et compositions permettant d'inhiber l'isoforme 1 de l'impdh
UA95455C2 (ru) Макроциклические ингибиторы репликации вируса гепатита с
TN2010000468A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
BRPI0510858A (pt) composição, composto e método para administrar um agente biologicamente ativo a um animal necessitando o mesmo
UA84579C2 (ru) Макроциклические карбоновые кислоты и ацилсульфонамиды как ингибиторы репликации вируса гепатита с